Kornimate/medical-research-clean huggingface dataset:
a low age (advanced glycation end-product) dietary intervention for breast cancer survivors

Conditions: Breast Cancer

Summary: the scientific premise for this study is the known impact of overweight/obesity on breast cancer risk and outcomes, the association between advanced glycation end-products (age) and high fat, highly processed foods common in western diets, and the preclinical evidence suggesting a link between age and breast cancer independent of weight. the association between dietary and serum age in breast cancer survivors and prognosis has not been previously evaluated. however, preclinical studies suggest that age may represent a novel, lifestyle-linked, modifiable, prognostic biomarker, which could be targeted through lifestyle (diet and exercise) and/or pharmaceutical interventions to improve breast cancer prognosis. the proposed study will pave the way for a large scale randomized controlled trial to evaluate the impact of a low age diet on weight (bmi), known (il-6 and crp) and novel (age and rage) prognostic biomarkers, and ultimately on breast cancer prognosis.


Eligibility criteria:
inclusion criteria: * diagnosis of breast cancer, any subtype, stage i-iii, within the last 36 months, who have completed primary therapy of their breast cancer (surgery, radiation, and chemotherapy). must be at least 4 weeks post their last chemotherapy or radiation therapy. concurrent hormonal therapy is allowed. * at least 18 years of age. * determined to have a high age diet at baseline (dietary age intake greater than 14 eq/day as assessed by food frequency questionnaire). * ability to understand and willingness to sign an irb approved written informed consent document. exclusion criteria: * diagnosis of diabetes. * history of eating disorder or body dysmorphic disorder. * active tobacco use (tobacco is a source of advanced glycation end products). * active participation in other dietary or physical activity clinical trials or community interventions. * taking and unwilling/unable to stop taking b-6 (pyridoxamine), b1 (thiamine) or metformin (all known age inhibitors).
bioequivalency study of torsemide tablets under fed conditions

Conditions: Edema

Summary: the objective of this study was the bioequivalence of a roxane laboratories' torsemide tablets, 20 mg, to demadex® tablets, 20 mg (roche) under fed conditions using a single-dose, 2-treatment, 2-period, crossover design.


Eligibility criteria:
inclusion criteria: * no clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening. exclusion criteria: * positive test for hiv, hepatitis b, or hepatitis c. * treatment with known enzyme altering drugs. * history of allergic or adverse response to torsemide or any comparable or similar product.
the clinical application of eit in clinically ill patients: a cross-sectional study

Conditions: Electrical Impedance Tomography (EIT)

Summary: the application of electrical impedance tomography (eit) in intensive care is increasing. it can provide additional information on individual respiratory physiology of patients, enabling clinicians or respiratory therapists to monitor patients' respiratory responses to different ventilator settings, respiratory treatment methods or clinical evolution, and thus achieve more personalized mechanical ventilation methods. although this technology provides a large amount of valuable information, there is still uncertainty about how to use it and interpret the results in critically ill patients. therefore, the evidence that eit-guided ventilation strategies can improve prognosis is still in its infancy. through this survey, the investigators aim to understand the current experiences and guiding roles of eit in clinical practice. the secondary objective is to learn about the current challenges of eit in clinical and practical settings, as well as the factors that promote or hinder the implementation of eit monitoring technology.


Eligibility criteria:
inclusion criteria: * occupation is "respiratory therapist or part-time respiratory therapy doctor/nurse"; * work city or area belongs to china; * to complete electronic questionnaires to fill out and submit. exclusion criteria: * work city or area not belongs to china; * the questionnaire is not completed or quit midway; * other invalid questionnaires.
registry study for patients with chronic hbv receiving nucleotide therapy

Conditions: Hepatitis B

Summary: this registry will remain open for approximately 5 years (4 years of enrollment + 1 year of follow up). subjects will be followed until orthotopic liver transplant (olt), resolution of liver decompensation, death, or conclusion of the registry.


Eligibility criteria:
key inclusion criteria: * estimated glomerular filtration rate (cockcroft-gault method)using actual body weight of ≥ 50 ml/min at time of entry into registry * negative serologies for hiv, hepatitis c virus (hcv), and/or hepatitis d virus (hdv) * no history of solid organ or bone marrow transplant * currently receiving or anticipated to receive anti-hbv nucleoside/nucleotide therapy within 6 months of inclusion into registry note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: hepatitis hepatitis b hbv olt meld renal safety liver transplant
effects of home-based respiratory muscle training progamme in individuals with ischemic heart disease

Conditions: Ischemic Heart Disease

Summary: the main objective of the present study is to verify whether respiratory muscle training programme (imt+emt; included both inspriratory and expiratory muscles), applied by telerehabilitation, is an effective intervention (versus placebo and versus inspiratory muscle training in isolation (imt)) in improving quality of life, cardiopulmonary function and physical and psychological state in people with ischemic heart disease. in addition, the aim is to determine whether respiratory muscle training (imt or imt+emt) is effective in enhancing the results obtained by a conventional cardiac rehabilitation programme on the aforementioned variables.


Eligibility criteria:
inclusion criteria: * presence of ischemic heart disease * age 18 years or older * cardiovascular clinical stability exclusion criteria: * any condition that contraindicate exercise training * inability to close the lips to hold the training device's mouthpiece (e.g., facial paralysis) * previous participation in a rehabilitation programme within the last 3 months * pregnancy * inability to adhere to remote monitoring

Keywords: respiratory muscle training cardiac rehabilitation quality of life cardiopulmonary function physical state psychological state telerehabilitation
susceptibility-guided sequential therapy for helicobacter pylori infection

Conditions: Helicobacter Pylori Infection

Summary: the main objective of this trial is to assess whether a sequential therapy strategy based on molecular antibiotic susceptibility testing (including clarithromycin and fluoroquinolone) for h. pylori infection will improve the eradication rate compared to an empirical therapy.

this trial is designed as a prospective, randomised, open-label, active-controlled and single-centre study. for empirical therapy group(control group), bismuth quadruple therapy will be an empirical first-line therapy, and high dose dual (proton-pump inhibitor + amoxicillin) treatment will be for rescue therapy if the first-line empirical treat failure. for the susceptibility-guided sequential therapy group, regimens were selected based on h. pylori susceptibility to clarithromycin and levofloxacin. the primary outcome is the first-line eradication rate in both groups, and the overall (including first- and rescue therapies) h. pylori eradication rates in both groups is one of the secondary outcomes. the eradication rates of h. pylori will be analysed by intention-to-treat analysis, modified intention-to-treat analysis and per-protocol analysis.

Eligibility criteria:
inclusion criteria: * h. pylori infection was determined using at least one of the following tests: 13c/14c-urea breath test (ubt), stool h. pylori antigen test, rapid urease test, and histological analysis within 4 weeks. * patients were naïve to h. pylori treatment. exclusion criteria: * allergy to any drug administered. * pregnancy and lactation. * major systemic diseases, such as severe cardiopulmonary or liver dysfunction. * complicated with active peptic ulcer disease, gastric cancer, or prior gastrectomy.

Keywords: helicobacter pylori drug resistance, microbial microbial sensitivity tests
diagnostic values of galectin-3, soluble st2 and bnp in predicting the clinical outcome of st-segment elevation myocardial infarction patients

Conditions: ST Elevation Myocardial Infarction; HF - Heart Failure; Stable Angina

Summary: an acute st-elevation myocardial infarction occurs due to occlusion of one or more coronary arteries, causing transmural myocardial ischemia which in turn results in myocardial injury or necrosis. acute myocardial infarction (ami) may lead to the development of heart failure (hf). accessible diagnostic tools commonly used in hf such as natriuretic peptides and (nyha) classiﬁcation reﬂect already overt clinical hf. troponin and creatine kinase reﬂect myocardial damage, but their usefulness in predicting long-term lvr is limited. recent guidelines on hf management stressed that hf onset may be delayed or prevented through certain interventions, such as pharmacotherapy ,post infarction rehabilitation, or modiﬁcation of hf risk factors. therefore, it is important to identify potential markers, which would be more informative of hf preclinical stages to recognize patients with an increased risk of hf onset, and to start treatment in advance (1) gal-3 participates in inﬂammation and pro ﬁbrotic pathways, while sst2 is a biomarker of inﬂammation, cardiac mechanical strain, and tissue ﬁbrosis, both of which may predict lvr (2). sst is a biomarker of inﬂammation, cardiac mechanical strain, and tissue ﬁbrosis(3). b_type natriuretic peptide (bnp) is elevated in acute myocardial infarction and is a quantitative biochemical marker related to the extent of infarction and left ventricular systolic dysfunction(4).


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years. 2. hospital admission due to ﬁrst-time stemi treated with ppci. exclusion criteria: * history of previous acute coronary syndrome, previously diagnosed hf or asymptomatic lv dysfunction with lvef \<50% or previously diagnosed signiﬁcant valvular disease or any other previously diagnosed structural heart disease severe renal dysfunction, severe liver disease, chronic inﬂammatory disease, current neoplastic disease

Keywords: galectin-3
clinical implication of the tunable crack sensor

Conditions: Blood Pressure

Summary: \[development of diagnosis algorism for paroxysmal arrhythmia using ultra-thin resistive membrane: a pilot study\] comparison of blood pressure via tunable crack sensor and invasive pressure wire

to develop a diagnosis algorism for paroxysmal arrhythmia using ultra-thin resistive membrane, we will compare the blood pressure measured via a tunable crack sensor and that measured by a invasive pressure wire

Eligibility criteria:
inclusion criteria: a case of suspected coronary artery disease at seoul national university hospital for the purpose of coronary angiography * at least 19 years old * if he/she hears enough explanation about clinical research and intends to participate in clinical research himself exclusion criteria: * under 19 years old * refusal to participate in clinical studies * if the cognitive function is weak enough not to understand the explanation of the clinical study and to make voluntary decisions accordingly

Keywords: blood pressure crack sensor
ectoin® mouth wash for the prevention and treatment of chemotherapy-induced oral mucositis

Conditions: Mucositis

Summary: this is a 3-week, non-interventional, observational study of patients undergoing chemotherapy (sutent) designed as a three-arm parallel study. in this study, the efficacy of ectoin containing mouthwash given prophylactically for the prevention of mucositis in patients before radio- and/or chemotherapy; as well as during radio- and/or chemotherapy for patients with mucositis compared to standard treatment should be investigated. the study doesn't intervene with routine treatment strategy.


Eligibility criteria:
inclusion criteria: * patients receiving radio- and/or chemotherapy (sutent) and suffering from mucositis * female or male individuals ≥ 18 years exclusion criteria: * male or female under 18 years * any disease that can, in the opinion of the treating physician, affect the outcome of the study * patients with known intolerance to one of the substances used * pregnancy

Keywords: non interventional study ectoin mouth wash mucositis chemotherapy radiotherapy
therapeutic effects of line dancing in people with ms

Conditions: Multiple Sclerosis

Summary: the objective of this study is to analyze the effects of line dancing on balance, anxiety, depression and quality of life for people with multiple sclerosis (pwms).

purpose: the objective of this study is to analyze the effects of line dancing on balance, anxiety, depression and quality of life for people with multiple sclerosis (pwms). methods: this study was conducted prospective parallel-group design study. 31 pwms were randomized two groups. the dance group undertook 60-minute sessions twice a week for four weeks and the control group did not do any particular training during this period. the outcome were measured using the berg balance scale (bbs), hospital anxiety and depression scale (hads), and multiple sclerosis quality of life-54 (msqol-54) by an evaluator blinded to the study.

Eligibility criteria:
inclusion criteria: * between 18-65 years, * edss \[22\]\<6, * mini-mental state examination score \>24. exclusion criteria: * exacerbations within the previous three months, * have other physical, neurological problems, * changeable health status. * havig a cardiovascular disorder

Keywords: line dance balance anxiety depression quality of life multiple sclerosis
pharmacokinetics of clg561 in patients with advanced age-related macular degeneration

Conditions: Age-related Macular Degeneration

Summary: the purpose of this study is to evaluate the safety, tolerability, and serum pharmacokinetics of clg561 in subjects with advanced age-related macular degeneration (amd).

subjects were divided into 5 cohorts, with the subjects in each cohort being administered a single ivt dose of clg561 in 1 of 5 concentration levels a-e, where a=lowest and e=highest. all subjects received active clg561. progress from one cohort to the next was time-lagged to allow for safety review. dosing was also time-lagged within each cohort. only one eye (designated as the study eye) was dosed per subject. post-dose safety assessments and ocular examination occurred immediately after the ivt injection and continued throughout the outpatient visits at pre-determined timepoints. collection of post-injection blood samples began after the ivt injection at pre-determined timepoints. subjects were followed for up to 84 days.

Eligibility criteria:
inclusion criteria: * diagnosis of age-related macular degeneration in study eye, as specified in protocol. * poor visual acuity in study eye, as specified in protocol. * willing to receive meningitis and pneumonia vaccinations at least 2 weeks prior to study treatment. * females must be post-menopausal and/or surgically sterile. * other protocol-defined inclusion criteria may apply. exclusion criteria: * treatments to the study eye within 28 days prior to study treatment, as specified in protocol. * any disease or medication expected to cause systemic or ocular immunosuppression. * participation in another interventional clinical study or use of any experimental treatment for amd within 12 weeks prior to study treatment. * other protocol-defined exclusion criteria may apply.

Keywords: first in human safety tolerability serum pk intravitreal (ivt) age-related macular degeneration amd geographic atrophy choroidal neovascularization
characteristics of patients with dementia who are screaming in nursing homes

Conditions: Dementia

Summary: patients with dementia develop behavioral problems over time. among these, the investigators object screams or cries or disruptives vocalizations. their cause is multifactorial and their management difficult in nursing homes. often this patients are polymedicated, sedated or/and isolated. many scientific studies are interested in drug and non-drug treatments. in this study, the investigators are looking for a profile for disruptives vocalizations's patients. thus, the investigators will study the global profile of demented patients residing in ehpad to determine if there are any similarities between them.


Eligibility criteria:
inclusion criteria: * aged 75 years old and more * living in nursing homes * dementia * agitation and disruptives vocalizations * twice and more interventions by the mobile gerontopsychiatry team exclusion criteria: - no follow-up after team intervention

Keywords: dementia disease disruptives vocalizations agitation cries profil characteristics
resident physician burnout and well-being

Conditions: Stress

Summary: pilot study shows that two hours of weekly protected non-clinical time is associated with decreased burnout and increased well-being in otolaryngology residents

burnout amongst physicians is high with resulting concern over quality of care. with burnout beginning early in training, much-needed data is lacking on interventions to decrease burnout and improve well-being amongst resident physicians. the primary objective was to design and evaluate the impact of a departmental-level burnout intervention for otolaryngology residents. the secondary objective was to describe how residents utilized and perceived the study intervention. all current residents in the department of otolaryngology at the university of minnesota were solicited for participation. inclusion criteria included all residents willing to complete the study protocol. exclusion criteria included the principal investigator. all 19 eligible residents consented to participate. all participants were assigned two hours of weekly, protected non-clinical time alternating with a control period of no intervention at 6 week intervals. burnout was measured by the maslach burnout inventory (mbi) and mini-z questionnaire (mini-z). well-being was measured by the resident and fellow well-being index (wbi) and a quality-of-life (qol) single-item self-assessment (sa). in addition to baseline demographic survey, participants completed the aforementioned surveys at approximately 6-week intervals from october 2017 to july 2018.

Eligibility criteria:
inclusion criteria: - all resident physicians (pgy1 - pgy5) in the department of otolaryngology that were willing to complete the study protocol exclusion criteria: - principal investigator(s) were excluded from participation
effects of l-carnitine in amyotrophic lateral sclerosis patients with chchd10 mutations

Conditions: Amyotrophic Lateral Sclerosis (ALS)

Summary: the study was designed as a single-center, open-label, single-arm pilot study to estimate the safety and efficacy l-carnitine in als patients with chchd10 mutations.

the study was designed as a single-center, open-label, single-arm pilot study and was performed at the als inpatient clinic of the xuanwu hospital in beijing, china. als patients with chchd10 mutations were recruited to participate in the clinical trial. the patients were given l-carnitine therapy administered every 8 weeks, consisting of 1g l-carnitine diluted in 500 ml of 0.9% sodium chloride solution via intravenous infusion once daily. each treatment cycle lasted 2 weeks, repeated at 8-week intervals for a total of 3 cycles, with l-carnitine 1g is administered orally once daily during the intervals between intravenous therapies. primary end point was the changes of als-frs-r scores, and secondary end points were the changes of plasm nfl level, fvc%, weight and alsaq-40 scores. eligible patients were assessed at baseline and after 2, 10, 12, 20 and 30 weeks. at each visit, a detailed neurological examination, including assessment of general nerve function as well as quantitative and qualitative evaluation of the motor system, were performed for the patients. all adverse events (aes) encountered and any serious events were to be recorded as true. severity was graded according to the modified who criteria for toxicity (http://www.regsource. com/_adverse_event_reporting/_adverse_event_ reporting.html) where applicable.

Eligibility criteria:
inclusion criteria: * male or female, 18-80 years old * als diagnosed as definite or probable as defined by the world federation of neurology revised el escorial criteria * carrying pathogenic chchd10 mutations * capable of providing informed consent and following trial procedures * forced vital capacity (fvc) \>40% of predicted value for gender, height, and age at the screening visit * subjects develop at less moderate degree of motor dysfunction, with als-frs-r total scores less than 46 * both male and female patients must agree to use adequate birth control for the whole duration of the study within 30 weeks * subjects are willing and expected to complete the 30-week follow up, including 3 times hospitalization. exclusion criteria: * presence of tracheostomy * history of known allergy to l-carnitine * abnormal liver function defined as ast and/or alt \> 3 times the upper limit of the normal * renal insufficiency as defined by egfr \< 60 ml/min/1.73m2 * pregnant women or women currently breastfeeding * clinically significant unstable medical condition (other than als) that would pose a risk to the subject if they were to participate in the study * anything that, in the opinion of the site investigator, would place the subject at increased risk or preclude the subject's full compliance with or completion of the study.

Keywords: amyotrophic lateral sclerosis l-carnitine chchd10 flail arm syndrome
prc with meniscal allograft arthroplasty for wrist osteoarthritis

Conditions: Wrist Osteoarthritis

Summary: this study plans to learn more about the effect of adding tissue graft for wrist osteoarthritis reconstruction procedures. previous studies have shown better allograft stability, and no documented foreign body reaction than with silicone and other synthetic materials.


Eligibility criteria:
inclusion criteria: * symptomatic wrist arthritis associated with slac or snac pathology * patients 30 years or older or 80 years or younger exclusion criteria: * patients younger than 29 years or older than 80 years * history of previous surgery related to wrist osteoarthritis